Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
The DOI matches its Crossref record.
Abstract
The purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (1) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl‐α tocopherol, and (3) in sterically stabilized, long‐circulating “Stealth” liposomes composed of hydrogenated soy phosphatidylcholine/cholesterol/ polyethylene glycol‐distearoylphosphatidylethanolamine. The doxorubicin formulations were used to treat recently implanted and well‐established, growing primary mouse mammary carcinomas, and to inhibit the development of spontaneous metastases from intra‐mammary tumor implants. In the treatment of recently implanted primary tumors, the formulations were given in 3 i.v. injections over 15 days, starting 3 or 10 days after tumor implantation. In the treatment of well‐established primary tumors, the mice received 4 i.v. injections over 22 days, starting an average 38 days after tumor implantation. In the preventive treatment against metastases, the formulations were given in 4 i.v. injections over 22 days, starting 22 days or 58 days after primary tumor implantation. The Stealth liposome formulation was significantly more effective than the conventional liposome formulation or the free drug in reducing the incidence of metastases from intra‐mammary implants of tumor MC19 and tumor MC65, in curing mice with recent implants of tumor MC2A, tumor MC2B, and tumor MC65, and in increasing the 8‐week survival of mice with well‐established implants of tumor MC2B. It is concluded that the long circulation time of the Stealth liposome doxorubicin formulation accounts for its superior therapeutic effectiveness. © 1992 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586
Optimizing Liposomes for Delivery of Chemotherapeutic Agents to Solid Tumors
Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., & Papahadjopoulos, D. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01426-1 · Cited by 1,263
Novel applications of liposomes
Lasic, D. (1998) · Trends in Biotechnology · doi:10.1016/s0167-7799(98)01220-7 · Cited by 867
Self-citationMuggia, F. M., Hainsworth, J. D., Jeffers, S., Miller, P., Groshen, S., Tan, M., Roman, L., Uziely, B., Muderspach, L., Garcia, A., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.987 · Cited by 647
Recent advances in tumor-targeting anticancer drug conjugates
Jaracz, S., Chen, J., Kuznetsova, L. V., & Ojima, I. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.084 · Cited by 490
Gabizon, A., & Martin, F. (1997) · Drugs · doi:10.2165/00003495-199700544-00005 · Cited by 478
Self-citationUziely, B., Jeffers, S., Isacson, R., Kutsch, K., Wei-Tsao, D., Yehoshua, Z., Libson, E., Muggia, F. M., & Gabizon, A. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1777 · Cited by 477
Long-circulating (sterically stabilized) liposomes for targeted drug delivery
Allen, T. M. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90314-x · Cited by 445
Lasic, D. D., & Papahadjopoulos, D. (1995) · Science · doi:10.1126/science.7871422 · Cited by 432
Self-citationNanoparticle Characterization: State of the Art, Challenges, and Emerging Technologies
Cho, E. J., Holback, H., Liu, K. C., Abouelmagd, S. A., Park, J., & Yeo, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300697h · Cited by 382
Allen, T. M. (1994) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(94)90016-7 · Cited by 321
Doxorubicin in sterically stabilized liposomes
Lasic, D. D. (1996) · Nature · doi:10.1038/380561a0 · Cited by 308
Self-citationPharmacokinetics of long-circulating liposomes
Allen, T. M., Hansen, C. B., & de Menezes, D. E. L. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00029-7 · Cited by 305
Ranson, M. R., Carmichael, J., O'Byrne, K., Stewart, S., Smith, D., & Howell, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3185 · Cited by 293
Siegal, T., Horowitz, A., & Gabizon, A. (1995) · Journal of neurosurgery · doi:10.3171/jns.1995.83.6.1029 · Cited by 232
Stealth® liposomes: from theory to product
Cˇeh, B., Winterhalter, M., Frederik, P. M., Vallner, J. J., & Lasic, D. D. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00456-5 · Cited by 191
Self-citationNielsen, U. B., Kirpotin, D. B., Pickering, E. M., Hong, K., Park, J. W., Refaat Shalaby, M., Shao, Y., Benz, C. C., & Marks, J. D. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(02)00256-2 · Cited by 177
Working, P. K., Newman, M. S., Huang, S. K., Mayhew, E., Vaage, J., & Lasic, D. D. (1994) · Journal of Liposome Research · doi:10.3109/08982109409037065 · Cited by 163
Self-citationFüredi, A., Szebényi, K., Tóth, S., Cserepes, M., Hámori, L., Nagy, V., Karai, E., Vajdovich, P., Imre, T., Szabó, P., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.010 · Cited by 100
Metadata
- Authors
- Vaage, J., Mayhew, E., Lasic, D., & Martin, F.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1992-07-30
- Volume
- 51
- Issue
- 6
- Pages
- 942-948
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2012879110
- Cited by
- 150
- References
- 0
- FWCI
- 14.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.